Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,555,556
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
528,456
-
Shares change
-
+10,983
-
Total reported value, excl. options
-
$1,670,206
-
Value change
-
+$34,959
-
Number of buys
-
6
-
Number of sells
-
-8
-
Price
-
$3.16
Significant Holders of Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) as of Q2 2025
20 filings reported holding LPCN - Lipocine Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 528,456 shares
of 5,555,556 outstanding shares and own 9.51% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (224,876 shares), BlackRock, Inc. (89,272 shares), GEODE CAPITAL MANAGEMENT, LLC (61,076 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (46,019 shares), RENAISSANCE TECHNOLOGIES LLC (34,797 shares), DIMENSIONAL FUND ADVISORS LP (23,862 shares), STATE STREET CORP (18,626 shares), NORTHERN TRUST CORP (13,160 shares), BARCLAYS PLC (9,412 shares), and BANK OF AMERICA CORP /DE/ (2,587 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.